191 related articles for article (PubMed ID: 32720471)
1. Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes.
Alshawli AS; Wurdak H; Wood IC; Ladbury JE
Mol Genet Genomic Med; 2020 Oct; 8(10):e1429. PubMed ID: 32720471
[TBL] [Abstract][Full Text] [Related]
2. REST is a novel prognostic factor and therapeutic target for medulloblastoma.
Taylor P; Fangusaro J; Rajaram V; Goldman S; Helenowski IB; MacDonald T; Hasselblatt M; Riedemann L; Laureano A; Cooper L; Gopalakrishnan V
Mol Cancer Ther; 2012 Aug; 11(8):1713-1723. PubMed ID: 22848092
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.
Aguilera DG; Das CM; Sinnappah-Kang ND; Joyce C; Taylor PH; Wen S; Hasselblatt M; Paulus W; Fuller G; Wolff JE; Gopalakrishnan V
J Neurooncol; 2009 Jul; 93(3):303-18. PubMed ID: 19148581
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism.
Hrgovic I; Doll M; Pinter A; Kaufmann R; Kippenberger S; Meissner M
Exp Dermatol; 2017 Feb; 26(2):194-201. PubMed ID: 27487811
[TBL] [Abstract][Full Text] [Related]
6. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional repressor REST drives lineage stage-specific chromatin compaction at
Dobson THW; Tao RH; Swaminathan J; Maegawa S; Shaik S; Bravo-Alegria J; Sharma A; Kennis B; Yang Y; Callegari K; Haltom AR; Taylor P; Kogiso M; Qi L; Khatua S; Goldman S; Lulla RR; Fangusaro J; MacDonald TJ; Li XN; Hawkins C; Rajaram V; Gopalakrishnan V
Sci Signal; 2019 Jan; 12(565):. PubMed ID: 30670636
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.
Yuan J; Llamas Luceño N; Sander B; Golas MM
Cell Oncol (Dordr); 2017 Jun; 40(3):263-279. PubMed ID: 28429280
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.
Mascaro-Cordeiro B; Oliveira ID; Tesser-Gamba F; Pavon LF; Saba-Silva N; Cavalheiro S; Dastoli P; Toledo SRC
Childs Nerv Syst; 2018 Aug; 34(8):1497-1509. PubMed ID: 29785653
[TBL] [Abstract][Full Text] [Related]
10. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
Ecker J; Oehme I; Mazitschek R; Korshunov A; Kool M; Hielscher T; Kiss J; Selt F; Konrad C; Lodrini M; Deubzer HE; von Deimling A; Kulozik AE; Pfister SM; Witt O; Milde T
Acta Neuropathol Commun; 2015 Apr; 3():22. PubMed ID: 25853389
[TBL] [Abstract][Full Text] [Related]
11. HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma.
da Cunha Jaeger M; Ghisleni EC; Cardoso PS; Siniglaglia M; Falcon T; Brunetto AT; Brunetto AL; de Farias CB; Taylor MD; Nör C; Ramaswamy V; Roesler R
J Mol Neurosci; 2020 Jun; 70(6):981-992. PubMed ID: 32056089
[TBL] [Abstract][Full Text] [Related]
12. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.
Milde T; Oehme I; Korshunov A; Kopp-Schneider A; Remke M; Northcott P; Deubzer HE; Lodrini M; Taylor MD; von Deimling A; Pfister S; Witt O
Clin Cancer Res; 2010 Jun; 16(12):3240-52. PubMed ID: 20413433
[TBL] [Abstract][Full Text] [Related]
13. Expression of the Neural REST/NRSF-SIN3 Transcriptional Corepressor Complex as a Target for Small-Molecule Inhibitors.
Jayaprakash S; Le LTM; Sander B; Golas MM
Mol Biotechnol; 2021 Jan; 63(1):53-62. PubMed ID: 33130996
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of KCASH2 and KCASH3, 2 novel Cullin3 adaptors suppressing histone deacetylase and Hedgehog activity in medulloblastoma.
De Smaele E; Di Marcotullio L; Moretti M; Pelloni M; Occhione MA; Infante P; Cucchi D; Greco A; Pietrosanti L; Todorovic J; Coni S; Canettieri G; Ferretti E; Bei R; Maroder M; Screpanti I; Gulino A
Neoplasia; 2011 Apr; 13(4):374-85. PubMed ID: 21472142
[TBL] [Abstract][Full Text] [Related]
16. Role of MXD3 in proliferation of DAOY human medulloblastoma cells.
Barisone GA; Ngo T; Tran M; Cortes D; Shahi MH; Nguyen TV; Perez-Lanza D; Matayasuwan W; Díaz E
PLoS One; 2012; 7(7):e38508. PubMed ID: 22808009
[TBL] [Abstract][Full Text] [Related]
17. MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter.
Formisano L; Guida N; Laudati G; Mascolo L; Di Renzo G; Canzoniero LM
J Pharmacol Exp Ther; 2015 Feb; 352(2):236-43. PubMed ID: 25467131
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.
Venturelli S; Berger A; Böcker A; Busch C; Weiland T; Noor S; Leischner C; Schleicher S; Mayer M; Weiss TS; Bischoff SC; Lauer UM; Bitzer M
PLoS One; 2013; 8(8):e73097. PubMed ID: 24023672
[TBL] [Abstract][Full Text] [Related]
19. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
Nör C; de Farias CB; Abujamra AL; Schwartsmann G; Brunetto AL; Roesler R
Childs Nerv Syst; 2011 Jun; 27(6):897-901. PubMed ID: 21560052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
